Back | Next |
home / stock / lexx / lexx message board
Subject | By | Source | When |
---|---|---|---|
So we're done? | adam69 | investorshub | 05/04/2023 4:38:44 PM |
Thanks for sneaking that one through Bunka. | Shawking | investorshub | 05/04/2023 4:05:57 PM |
5+year low .054 CENTS PRE SPLIT now lets see | PotsandPans420 | investorshub | 05/03/2023 8:44:09 PM |
NetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zack | NetworkNewsWire | investorshangout | 05/03/2023 8:11:59 PM |
Caught that dip @ 1.65 | codfather | investorshub | 05/03/2023 2:56:46 PM |
good read | Tech99989 | investorshub | 05/03/2023 11:07:59 AM |
$LEXX what do you make of this data? | codfather | investorshub | 05/03/2023 2:34:21 AM |
good read | all4weed | investorshub | 05/02/2023 10:19:36 PM |
oh yeah news for the day | PotsandPans420 | investorshub | 05/02/2023 8:13:55 PM |
overpaid underperform -- great ride for bunka and | harlem111 | investorshub | 05/02/2023 5:20:40 PM |
$LEXX Have a look at this | harlem111 | investorshub | 05/02/2023 12:24:32 PM |
Bunka is also making what $400k per year. | PotsandPans420 | investorshub | 05/02/2023 12:18:46 AM |
thank you but really sick of years of | harlem111 | investorshub | 05/01/2023 8:16:41 PM |
Ted Ohashi-Let's Toke Business | Shawking | investorshub | 05/01/2023 8:02:05 PM |
I think you tend to forget who the | codfather | investorshub | 05/01/2023 5:57:08 PM |
BUNKA IS A SELF SERVING POS -- DEALS | harlem111 | investorshub | 05/01/2023 4:51:01 PM |
Bunka said in those interviews with Ted that | PotsandPans420 | investorshub | 05/01/2023 3:11:10 PM |
say NO to 3, 4, and 5 questions, | all4weed | investorshub | 05/01/2023 5:38:52 AM |
He has conned again, had posted in shareholder | all4weed | investorshub | 05/01/2023 5:14:26 AM |
Codfather, consider VOTING NO against repricing options as | Tech99989 | investorshub | 04/29/2023 8:01:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
3.3%Change Percent:
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...